Niagen Bioscience, Inc. (NAGE)
Nasdaq: NAGE · Medicinal Chemicals & Botanical Products · Los Angeles, CA · filing with the SEC since 2007
Grade6.8
◀ Past 5.8● Present 7.0▶ Future 7.7
Who owns Niagen Bioscience, Inc.
As filed with the SECHolders of 5% or more
1
Blackrock, Inc. holds 5.2% of Common Stock, as its SCHEDULE 13G filed Jul 29, 2026 says.
Directors and officers
10
report now, of 31 people on the record since 2008. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Jan 30, 2026 · Common Stock · reported falling below 5%, from 5.04% in Oct 31, 2025
What NAGE reports owning in othersstakes of 5% or more, and other ties
10 subsidiaries in 6 countries, from the list filed with the 10-K filed Mar 4, 2026.
Insider tradesForm 4
0sales
2purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 40 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer | 0 | $0 | 0 | 2 | $0 |